- Licensed anti-HIV drugs
- Discontinued anti-HIV drugs
- Experimental anti-HIV drugs and treatments
- Herbal and naturopathic treatments
- Failed anti-HIV drugs
- 935U83
- A-74704, A-77003 & A-80987
- AL-721
- ALX40-4C
- AMD3100
- Aplaviroc
- Ampligen
- Atevirdine
- Aztec
- BB-10010
- Butyl DNJ
- Capravirine
- Castanospermine
- Compound Q
- DAPD
- DFC (dexelvucitabine)
- DMP-450
- dOTC
- DPC 083
- DPC 681 and DPC 684
- DPC 961 and DPC 963
- Emivirine
- FLT
- GEM 92
- GW420867X
- KNI-272
- L-697,661
- Lithium gamma-linolenate
- Lodenosine
- Loviride
- Oxpentifylline
- Quinotaline
- RO033-4649
- Ro 24-7429
- SC-52151 & SC-55389A
- SID791
- SPC3
Failed anti-HIV drugs
- 935U83
- A-74704, A-77003 & A-80987
- AL-721
- ALX40-4C
- AMD3100
- Aplaviroc
- Ampligen
- Atevirdine
- Aztec
- BB-10010
- Butyl DNJ
- Capravirine
- Castanospermine
- Compound Q
- DAPD
- DFC (dexelvucitabine)
- DMP-450
- dOTC
- DPC 083
- DPC 681 and DPC 684
- DPC 961 and DPC 963
- Emivirine
- FLT
- GEM 92
- GW420867X
- KNI-272
- L-697,661
- Lithium gamma-linolenate
- Lodenosine
- Loviride
- Oxpentifylline
- Quinotaline
- RO033-4649
- Ro 24-7429
- SC-52151 & SC-55389A
- SID791
- SPC3
latest aidsmap news
- Traditional healers could play key role in ART rollout
- HIV testing for mothers and children must expand, UN report shows
- London hospital to test new HIV vaccine candidate
- Counselling sessions can reduce reported risky sex by HIV-positive gay men
- HIV diagnoses in European MSM have almost doubled since 2000, UK tops the list
- Older HIV-positive gay men as likely to have risky sex as younger gay men with HIV
- Mbeki's opposition to ARVs cost 330,000 lives, shows study
- Universal testing and treatment could reduce new HIV infections in southern Africa by 95% in 10 years
- Record number of people accessing HIV care in the UK
- Treatment during primary HIV infection has limited benefit